Emerald Health Therapeutics Launches Flavoured Cannabis Oils, Expanding SYNC(TM) Product Line

Combination of appealing natural flavourings and terpenes offers unique consumer experience Emerald also launches new SYNC CBD nanoemulsion-based Fast Action Spray in BC and Saskatchewan Vancouver, British Columbia–(Newsfile Corp. – October 19, 2020) – Emerald Health Therapeutics, Inc. (TSXV: EMH) (OTCQX: EMHTF) (“Emerald”) has expanded its SYNCTM product line with the launch of new uniquely flavoured CBDContinue reading “Emerald Health Therapeutics Launches Flavoured Cannabis Oils, Expanding SYNC(TM) Product Line”

Emerald Health Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update

 – September 1, 2020) – Emerald Health Therapeutics, Inc. (TSXV: EMH) (OTCQX: EMHTF) (“Emerald”) reported financial results for the three and six months ended June 30, 2020. Full versions of the Company’s unaudited condensed interim consolidated financial statements and MD&A can be found on SEDAR at www.sedar.com. “The second quarter was a very solid quarter in allContinue reading “Emerald Health Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update”

Emerald Health Therapeutics Launches New Fast-Acting Cannabis Spray Products Offering Consumers Significantly Improved Predictability and Control of Effects

SYNC(TM) Nano Fast Action Spray uses nanoemulsion technology to enable rapid onset and shorter duration of effects; the first THC product is in-market, with CBD to follow  –  Emerald Health Therapeutics, Inc. (TSXV: EMH) (OTCQX: EMHTF) (“Emerald”)  has launched the first product in its adult-use SYNCTM Nano fast-acting cannabis spray product line. SYNCTM 15 Nano THC FastContinue reading “Emerald Health Therapeutics Launches New Fast-Acting Cannabis Spray Products Offering Consumers Significantly Improved Predictability and Control of Effects”

Emerald Health Therapeutics Announces New At-the-Market Equity Program

 – August 13, 2020) – Emerald Health Therapeutics, Inc. (TSXV: EMH) (OTCQX: EMHTF) (the “Company”) today announced that it has established an at-the-market equity program (“ATM Program”) that allows the Company to issue common shares from treasury (“Common Shares”) having an aggregate gross sales price of up to $3.25 million to the public from time toContinue reading “Emerald Health Therapeutics Announces New At-the-Market Equity Program”

Emerald Health Therapeutics and Quinto Resources Enter into Share Purchase Agreement for Sale of Quebec Cannabis Business

– July 31, 2020) – Emerald Health Therapeutics, Inc. (TSXV: EMH)  (“Emerald”) and Quinto Resources Inc. (“Quinto”) (TSXV: QIT) today announced that they have entered into a share purchase agreement dated July 30, 2020 (the “Agreement”) in respect of the sale of Emerald’s wholly-owned subsidiaries, Verdélite Sciences, Inc. (“Verdélite Sciences”) and Verdélite Property Holdings, Inc.Continue reading “Emerald Health Therapeutics and Quinto Resources Enter into Share Purchase Agreement for Sale of Quebec Cannabis Business”

Emerald Health Therapeutics’ Pure Sunfarms Joint Venture Begins Shipping Branded Products to Manitoba

Pure Sunfarms remains top-selling dried cannabis brand with Ontario Cannabis Store1 and achieves sales records in July — Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) today announced that its joint venture for large-scale, low-cost, high-quality cannabis production, Pure Sunfarms, has begun shipping branded, packaged dried flower products to Manitoba’s licensed private sector retailers, withContinue reading “Emerald Health Therapeutics’ Pure Sunfarms Joint Venture Begins Shipping Branded Products to Manitoba”

Emerald Announces $2.1 Million Prospectus Sale

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, May 21, 2020 (GLOBE NEWSWIRE) — Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF), has entered into a binding term sheet with a single Canadian institutional accredited investor (the “Investor”) under which the Investor has agreed, subjectContinue reading “Emerald Announces $2.1 Million Prospectus Sale”